## Virax Biolabs Expands Reach in UK and Ireland with ImmuneSelect Distribution Deal
Virax Biolabs Group Limited (VRAX) is making waves in the UK and Ireland with a new distribution agreement. The company has partnered with Europa Biosite to commercialize its groundbreaking ImmuneSelect Research Use portfolio, a suite of profiling solutions designed to assess adaptive immunity.
This strategic move is poised to significantly expand Virax Biolabs’ commercial footprint in the UK and Ireland, making ImmuneSelect readily accessible to researchers and pharmaceutical companies. The partnership signifies a major step forward for Virax Biolabs, building upon the successful launch of ImmuneSelect earlier this year within the ViraxImmune T-Cell diagnostic platform.
“ImmuneSelect is an important suite of profiling solutions for assessing adaptive immunity…,” commented James Foster, CEO of Virax Biolabs. “We believe this partnership will meaningfully expand our commercial footprint in the UK and Ireland and make ImmuneSelect accessible to researchers and pharmaceutical companies…”
Europa Biosite is equally enthusiastic about the partnership. “We look forward to leveraging our commercial infrastructure to quickly deliver and provide local technical support to ensure that ImmuneSelect is available in the UK & Ireland,” said Martijn Blommaart, Director of Supplier Development at Europa Biosite.
The ImmuneSelect portfolio is designed to evaluate T-Cell driven immunity, offering insights into the understanding and early characterization of symptoms associated with post-viral syndromes, including Long COVID. The portfolio features peptide pools encompassing epitopes from pathogens linked to post-viral syndromes.
This latest agreement follows Virax Biolabs’ August announcement of a distribution deal for (RT) PCR Mpox virus detection kits in select European and Gulf countries. The RT PCR Mpox virus detection kits have received approval for sale in Europe and authorization from the Medicines and Healthcare Products Regulatory Agency in the United Kingdom.
Virax Biolabs continues to solidify its position as a leader in the field of immune research and diagnostics. The company’s commitment to developing innovative solutions that address emerging health challenges, such as post-viral syndromes, is driving its growth and impact in the global market.